Outstanding Achievement Award, Urologic Oncology Branch, National Cancer Institute, 2002
CIAO Award for Medicine, 1995
Chairman of the Prostate Committee of the National Cancer Institute’s Prostate, Lung,
Disclosure of Financial Interests with Industry
Editor or Editorial Boards:
Washington University and its physicians are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians work collaboratively with pharmaceutical or medical device companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our faculty physicians are paid by these commercial companies to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this web site, physicians earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.
Dr. Gerald L. Andriole reported the following earned financial interests during calendar year 2011. Move your mouse over a header for more info.
Royalties: When a faculty member invents or conceives a new or improved process or product, the company that manufactures the product will make royalty payments to the faculty member. Royalty payments usually are a small percentage of the company’s revenue related to that product.
Equity: Equity is an ownership interest in a company. Faculty members may be paid for their service to a company in stock or the option to obtain stock.
Consulting and Advisory Boards: Faculty may be paid to provide expertise to a company by being their consultant, or by serving on an advisory board.
Speaker Fees: Companies may pay faculty to speak to professional audiences about their products.
|Amgen || || ||$10,001-$25,000 || |
|GlaxoSmithKline || || ||$1,000-$10,000 ||$1,000-$10,000 |
|Augmenix || ||Yes || || |
|Envisioneering || ||Yes || || |
|Cambridge Endosciences || ||Yes || || |
To learn more about Washington University's policies on collaborations with industry, click here
Associate Editor, The 5 Minute Urology Consult, 2008-present
Community Editor, Urologic Surgery, American College of Surgeons Web Portal, 2007-present
Editorial Board, Cornell University Medical College Reports on Men’s Urologic Health, 2006-present
Associate Editor, The Journal of Men’s Health & Gender, 2003-present
Urology Times, Hands-On Editor, 2002-present
Editor-in-Chief, Yearbook of Urology, 1997-present
Editorial Board, Urology Research and Treatment, 1999-present
Editorial Board, Urologia Internationalis, 1997-present
Editorial Consultant, The Paget Society, 1999-present
The Prostate Journal, 1997-present
Editorial Board, Infections in Urology, 1991-present
Editorial Advisory Board, Surgical Rounds, 1990-present
Editorial Board, Annals of Surgical Oncology, 1997-2003
Journal of Urology
Journal of the National Cancer Institute
New England Journal of Medicine
Journal of Clinical Oncology
Major National Committees
Steering Committee, Prostate Cancer Chemoprevention Trial
Steering Committee, NIH PLCO Cancer Screening Trial
Chairman, Prostate Subcommittee NCI PLCO Cancer Screening Trial
Medical Advisory Committee, Prostate Intervention Versus Observation Trial
Commission on Cancer of the American College of Surgeons
Cochrane Collaboration in Prostatic Diseases
AUA/Pfizer Visiting Professor Review Board
Steering Committee, CAMUS Trial (NIH/NIDDK)
Chairman, Steering Committee, REDUCE Trial (Dutasteride Chemoprevention Trial)
NCI, Biorepository Scientific Advisory Panel
Panel Member, Blue Ribbon Prostate Institution Oral Examiner, Exam Committee, American
Selected or Recent Journal Articles
Vemana G, Hamilton RJ, Andriole GL, Freedland SJ. Chemoprevention of Prostate Cancer. Annu Rev Med. 2013 Nov 4.
Vemana G, Andriole GL. Editorial comment. Urology. 2013 Nov
Sandhu GS, Nepple KG, Tanagho YS, Andriole GL. Prostate cancer chemoprevention. Semin Oncol. 2013 Jun.
Sandhu GS, Andriole GL. Prostate cancer: Improvements in risk stratification of prostate cancer. Nat Rev Urol. 2013 Jun.
Haseebuddin M, Dehdashti F, Siegel BA, Liu J, Roth EB, Nepple KG, Siegel CL, Fischer KC, Kibel AS, Andriole GL, Miller TR. 11C-acetate PET/CT before radical prostatectomy: nodal staging and treatment failure prediction. J Nucl Med. 2013 May.
Sandhu GS, Andriole GL. Overdiagnosis of prostate cancer. J Natl Cancer Inst Monogr. 2012 Dec.
Andriole GL, McCullum-Hill C, Sandhu GS, Crawford ED, Barry MJ, Cantor A; CAMUS Study Group. The effect of increasing doses of saw palmetto fruit extract on serum prostate specific antigen: analysis of the CAMUS randomized trial. J Urol. 2013 Feb.
Andriole GL Jr. PSA screening and prostate cancer risk reduction. Urol Oncol. 2012 Nov-Dec.
Sandhu GS, Nepple KG, Tanagho YS, Andriole GL. Laparoscopic prostatectomy for prostate cancer: continued role in urology. Surg Oncol Clin N Am. 2013 Jan.
Tanagho YS, Andriole GL, Paradis AG, Madison KM, Sandhu GS, Varela JE, Benway BM. 2D versus 3D visualization: impact on laparoscopic proficiency using the fundamentals of laparoscopic surgery skill set. J Laparoendosc Adv Surg Tech A. 2012 Nov.
Grubb RL, Andriole GL, Somerville MC, Mahoney C, Manyak MJ, Castro R. The REDUCE Follow-Up Study: low rate of new prostate cancer diagnoses observed during a 2-year, observational, followup study of men who participated in the REDUCE trial. J Urol. 2013 Mar.
Sandhu GS, Andriole GL. Active Surveillance for Prostate Cancer: Barriers to Widespread Adoption. Eur Urol. 2012 Jun 30.
Lai HH, North CS, Andriole GL, Sayuk GS, Hong BA. Polysymptomatic, polysyndromic presentation of patients with urological chronic pelvic pain syndrome. J Urol. 2012 Jun.
Sutcliffe S, Grubb Iii RL, Platz EA, Ragard LR, Riley TL, Kazin SS,
Hayes RB, Hsing AW, Andriole GL; on behalf of the Urologic Diseases in
America Project. Non-steroidal anti-inflammatory drug use and the risk of benign prostatic hyperplasia-related outcomes and nocturia in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. BJU Int. 2012 Mar 19.
Strope SA, Yang L, Nepple KG, Andriole GL, Owens PL. Population based comparative effectiveness of transurethral resection of the prostate and laser therapy for benign prostatic hyperplasia. J Urol. 2012 Apr.